贝伐珠单抗联合化疗对肺癌患者 CT、CyFRA21-1、ProGRP 及预后的影响及护理干预。
Effects of Bevacizumab Combined with Chemotherapy on CT, CyFRA21-1, and ProGRP and Prognosis of Lung Cancer Patients under Nursing Intervention.
机构信息
Department of Thoracic Surgery, Zhangqiu District People's Hospital, Jinan 250200, China.
Department of Imaging, Yantai Yuhuangding Hospital Affiliated to Qingdao University, Yantai 264000, China.
出版信息
Comput Math Methods Med. 2022 Jul 14;2022:9422902. doi: 10.1155/2022/9422902. eCollection 2022.
OBJECTIVE
Molecular targeted drug therapy and chemotherapy are the main treatments for advanced non-small-cell lung cancer, and the combination of both has advantages in prolonging patients' progression-free survival and overall survival. This study investigated the effects of bevacizumab combined with chemotherapy under nursing intervention on CT, cytokeratin 19 fragment antigen 21-1 (CYFRA21-1), and gastrin-releasing peptide precursor (ProGRP) and prognosis of lung cancer patients.
METHODS
102 patients with non-small-cell lung cancer admitted to our hospital from January 2018 to May 2019 were divided into observation group and control group, with 51 cases each. The control group was treated with basic chemotherapy, and the observation group was treated with bevacizumab in combination with the control group, and both groups used nursing interventions. The clinical effects, CYFRA21-1 and ProGRP levels, baseline data, CT parameters, 24-month cumulative survival, and the effects of CYFRA21-1 and ProGRP on long-term survival and lung function were compared.
RESULTS
The disease control rate of the observation group was 94.12%, which was significantly higher than that of the control group (76.47%); after 7 d, 30 d, 60 d, and 90 d of treatment, the levels of CYFRA21-1 and ProGRP were statistically downregulated. The difference in lymph node metastasis, lesion diameter, plain Eff-Z, venous stage, and arterial stage normalized iodine concentrations (NIC) was statistically significant; the survival rate at 24 months in the observation group was 74.51% (38/51); the cumulative survival rate at 24 months in the control group was 52.94% (27/51), and the difference was statistically significant ( = 4.980, = 0.026). The cumulative survival rate at 24 months was significantly lower in patients with high expression of CYFRA21-1 and ProGRP compared with those with low expression of CYFRA21-1 and ProGRP. After treatment, in the observation group, the forceful spirometry (FVC), forceful expiratory volume in one second (FEV1), and FEV1/FVC levels were significantly different from those before treatment and were significantly different from those in the control group.
CONCLUSION
Bevacizumab in combination with standard chemotherapy regimens with nursing interventions could benefit patients with advanced non-small-cell lung cancer and had a good prospect of application.
目的
分子靶向药物治疗和化疗是非小细胞肺癌的主要治疗方法，两者联合使用在延长患者无进展生存期和总生存期方面具有优势。本研究探讨贝伐珠单抗联合化疗护理干预对 CT、细胞角蛋白 19 片段抗原 21-1（CYFRA21-1）和胃泌素释放肽前体（ProGRP）以及肺癌患者预后的影响。
方法
选择 2018 年 1 月至 2019 年 5 月我院收治的非小细胞肺癌患者 102 例，分为观察组和对照组，每组 51 例。对照组采用基础化疗，观察组在对照组基础上加用贝伐珠单抗，并均采用护理干预。比较两组的临床疗效、CYFRA21-1 和 ProGRP 水平、基线资料、CT 指标、24 个月累计生存率，以及 CYFRA21-1 和 ProGRP 对患者长期生存和肺功能的影响。
结果
观察组疾病控制率为 94.12%，明显高于对照组（76.47%）；治疗后 7、30、60、90 d，观察组患者 CYFRA21-1 和 ProGRP 水平均呈统计学下调趋势，淋巴结转移、病灶直径、平扫 Eff-Z、静脉期、动脉期碘标准化摄取值（NIC）比较差异有统计学意义；观察组 24 个月生存率为 74.51%（38/51），对照组为 52.94%（27/51），差异有统计学意义（ = 4.980， = 0.026）。CYFRA21-1 和 ProGRP 高表达患者 24 个月累计生存率明显低于低表达患者。治疗后观察组患者用力肺活量（FVC）、第 1 秒用力呼气容积（FEV1）和 FEV1/FVC 水平与治疗前比较差异有统计学意义，与对照组比较差异亦有统计学意义。
结论
贝伐珠单抗联合标准化疗方案加护理干预可使晚期非小细胞肺癌患者受益，具有良好的应用前景。
Zotero 插件